Navigation Links
Eskitis links with European life science researchers

Griffith University's Eskitis Institute will be the gateway for European scientists to access potential building blocks for new drugs and other products sourced from compounds created by Australian chemistry researchers.

In return, Australian researchers will also be able to draw on the chemical libraries of Europe after the signing of a Memorandum of Understanding hosted by the Australian Ambassador to Belgium, in Brussels on 16 May 2014.

The signatories are;

  • Therapeutic Innovation Australia (TIA), a Federal Government funding agency for strategic infrastructure for medical research
  • EU-OPENSCREEN, a European Research Infrastructure Initiative of Open Screening Platforms for Chemical Biology and
  • Compounds Australia - the national compound collection housed at Griffith's Eskitis Institute on Griffith's Nathan Campus.

Director of the Eskitis Institute for Drug Discovery, Professor Ronald J Quinn AM said research collaborations are vital in the search for new drugs to fight disease.

"Research needs to become more collaborative and multidisciplinary to succeed and we will get more value from Australian compounds if more exploration is being done," Professor Quinn said.

"Australian chemists will be able to have their compounds investigated by European scientists who are looking at things in different ways, and Australian biologists will have access to European compounds. The more people who are investigating the better."

Coordinator of the EU-OPENSCREEN consortium, Dr. Ronald Frank from Leibniz-Institut fr Molekulare Pharmakologie in Berlin Germany, is also enthusiastic about the exchange with Compounds Australia.

"This brings us a big step forward in joining forces with other continents to advance our understanding of how chemicals affect molecular mechanisms of complex biological processes," Dr Frank said.

"We now can combine the rich chemistry knowledge of Europe and Australia in our compound collections to promote the availability of safe and efficacious chemical products for unmet needs in medicine, nutrition, agriculture, and environment."

CEO of Therapeutic Innovation Australia, Dr Stewart Hay, said the Eskitis Institute and EU-OPENSCREEN commitment to share compounds will improve the probability of an important discovery.

"This collaboration between drug discovery researchers in Europe and Australia could potentially be the critical step leading to the discovery of our next blockbuster drug," Dr Hay said.


Contact: Helen Wright
Griffith University

Related biology news :

1. Incisive research links teeth with diet
2. New lab mice cut search for genetic links to disease by more than a decade
3. Geographic information systems demonstrate links between health and location
4. Desert to Rainforest global classroom links future teachers, classrooms in Phoenix and Panama
5. 50 years of bird poop links DDT with changing bird menus
6. New study links air pollution and early death in the UK
7. Fossil egg discovered in Lleida (Spain) links dinosaurs to modern birds
8. Research links extreme summer heat events to global warming
9. 10 new diabetes gene links offer picture of biology underlying disease
10. Researchers study links between conflict and fisheries in East Africa
11. 3 new genetic links to colorectal cancer
Post Your Comments:
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology: